See Total Prescribing Info OPDIVO® (nivolumab) is indicated for your treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed just after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or right after 3 or even more traces of systemic therapy that features autologous H